EN

On Echemi
For Type 2 diabetes & Weight-Loss
    
  • Liraglutide in the management of type 2 diabetes

  • Liraglutide for Weight Loss

  • Liraglutide is an acylated human (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cellsurface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells.
    MORE
    Liraglutide in the management of type 2 diabetes.jpg
  • Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs.
    MORE
    Liraglutide for Weight Loss .jpg

Global Liraglutide Market Trends

Liraglutide formulation was first approved by the U.S. Food and Drug Administration in 2010 and accounted for $418 million in sales that year. By the end of 2012, worldwide sales rose to $1.7 billion. The average retail price for Liraglutide formulation is more than $1,100 a month. By comparison, the average monthly retail price for injectable diabetes drug Byetta (exenatide), a similar drug manufactured by competitor AstraZeneca PLC, is about $905. Both drugs work to lower blood sugar by mimicking a hormone called glucagon-like peptide-1 (GLP-1).
ENTER
{specialTemplate.blobInfo_h.original_blob_name}
  • Clinical Trials Experience of Liraglutide in Type 2 Diabetes

  • Clinical Trials Experience of Liraglutide in Weight-Loss

  • Clinical Trials Experience of Liraglutide in Type 2 Diabetes .jpg
    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
    MORE
  • Clinical Trials Experience of Liraglutide in Weight-Loss.jpg
    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
    MORE
Huadong Medicine provides R&D production and documentation qualifications. Echemi is mainly responsible for marketing and supply chain services.

About Huadong Medicine Co.,Ltd

  • 1952

    Huadong Medicine established

  • 1993

    Hangzhou Zhongmei Huadong Medicine Co., Ltd Established

  • 2000

    IPO

  • 2006

    Acarbose have approved by FDA

  • Ciclosporin have approved by COS

  • 2011

    Sales Revenue exceeded 10 billion CNY

  • 2018

    Completed the acquisition of the UK company

R&D Center of Huadong Medicine

Over the years, Huadong Medicine has been continuously carrying out the technical transformation of GMP and FDA.
{specialTemplate.blobInfo_h.original_blob_name}
Buy Liraglutide .jpg

For More Pharmaceutical Information

Suggestions
Email:
Message:
Send Message